Physiological stimulation in preserved ejection fraction: A randomized trial

نویسندگان

چکیده

Abstract Funding Acknowledgements Type of funding sources: None. Introduction Right ventricular stimulation in the apex (RVAS) produce dysynchrony, leading to left ventricle systolic dysfunction (LVSD) some cases. Circumstances that can worsen LVSD are a high burden RVAS, and presence previous and/or intraventricular conduction disease (IVCD). Direct activation specialized system with physiological (PS) preserve this pattern shorten de QRS when impairment is proximal pacing site. Most studies PS has been focused on patients LVSD, few scarce evidences regarding pacients without LVSD. Objectives methods This parallel, single blinded, unicentric, randomized trial preserved mild reduced ejection fraction (LVEF) submitted pacemaker implantation due atrioventricular block (AVB), IVCD (wide QRS) an anticipated rate pacing. Patients were 1:1 RVAS vs followed for 6 months. Clinical, ECG, echocardiography analytic parameters compared. The primary endpoint was change LVEF at months each group. secondary endpoints changes end-diastolic diameter (LVEDD), duration, pro–B-type natriuretic peptide (NT-proBNP), NYHA class, Minnesota Living Heart Failure Questionnaire (MLWHFQ) Results study included 57 77±9,6 years. Of all patients, 53% treated 47% PS. There 2 crossover technical difficulties 1 patient apical scar. no differences basal duration (142.08±20,2 ms), (58.87±7,2%), NT-proBNP (3336,03±7258,68 pg/ml), or MLWHFQ (22,19±14,68), between both groups (Table 1). Acutely significant observed among (+16±29 ms group -17±25 group, p<0,001). At follow-up showed non-significant reduction 0.8±1.1% compared 5.1±1.7% (difference 4,26% IC 0,1-8,43 p=0,022). No values NT-ProBNP 2). Conclusions In requiring AVB, QTS preserves RVAS.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial.

BACKGROUND The mode of death has been well characterized in patients with heart failure and a reduced ejection fraction; however, less is known about the mode of death in patients with heart failure and a preserved ejection fraction (HFPEF). The purpose of this study was to examine the mode of death in patients with HFPEF enrolled in the Irbesartan in Heart Failure With Preserved Ejection Fract...

متن کامل

Heart Failure With Preserved Ejection Fraction

The Journal of the American Osteopathic Association July 2015 | Vol 115 | No. 7 432 From Henry Ford Wyandotte Downriver Cardiology in Brownstown, Michigan (Dr Rogers); West Suburban Medical Center in Oak Park, Illinois (Dr Gundala); Oakwood Southshore Medical Center in Trenton, Michigan (Dr Ramos); and Elmhurst Memorial Hospital in Illinois (Dr Serajian). Drs Gundala and Ramos are in their thir...

متن کامل

Heart Failure With Preserved Ejection Fraction

Symptomatic heart failure, despite preserved left ventricular (LV) ejection fraction, is a well-recognized phenomenon. This manifestation of diastolic dysfunction is associated with increased morbidity and mortality and can be attributed to a variety of pathogeneses, including diabetes mellitus, hypertension, infiltrative processes, and obesity. Unlike in systolic heart failure, where LV ejecti...

متن کامل

Heart Failure with Preserved Ejection Fraction

1. Demonstrate the association between heart failure with preserved ejection fraction (HFpEF) and survival. 2. Given a patient with heart failure (HF), recognize HFpEF on the basis of clinical signs and symptoms, physical examination, echocardiography, and radiographic findings. 3. Classify patients at high risk of hospitalization and mortality through assessing risk factors, clinical presentat...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Europace

سال: 2023

ISSN: ['1099-5129', '1532-2092']

DOI: https://doi.org/10.1093/europace/euad122.365